Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program
Open Access
- 1 September 2001
- journal article
- Published by Springer Nature in Journal of Urban Health
- Vol. 78 (3) , 550-567
- https://doi.org/10.1093/jurban/78.3.550
Abstract
This study examined whether costs associated with tuberculosis (TB) screening and directly observed preventive therapy (DOPT) among drug injectors attending a syringe exchange are justified by cases and costs of active TB cases prevented and examined the impact of monetary incentives to promote adherence on cost-effectiveness. We examined program costs and projected savings using observed adherence and prevalence rates and literature estimates of isoniazid (INH) preventive therapy efficacy, expected INH hepatoxicity rates, and TB treatment costs; we conducted sensitivity analyses for a range of INH effectiveness, chest X-ray (CXR) referral adherence, and different strategies regarding anergy among persons affected with human immunodeficiency virus (HIV). For 1,000 patients offered screening, incorporating real observed program adherence rates, the program would avert $179,934 in TB treatment costs, for a net savings of $123,081. Assuming a modest risk of TB among HIV-infected anergic persons, all strategies with regard to anergy were cost saving, and the strategy of not screening for anergy and not providing DOPT to HIV-infected anergic persons resulted in the greatest cost savings. If an incentive of $25 per person increased CXR adherence from the observed 31% to 50% or 100%, over a 5-year follow-up the net cost savings would increase to $170,054 and $414,856, respectively. In this model, TB screening and DOPT at a syringe exchange is a cost-effective intervention and is cost-saving compared to costs of treating active TB cases that would have occurred in the absence of the intervention. This model is useful in evaluating the cost impact of planned program refinements, which can then be tested. Monetary incentives for those referred for screening CXRs would be justified on a cost basis if they had even a modest beneficial impact on adherence.Keywords
This publication has 56 references indexed in Scilit:
- Provision of influenza and pneumococcal vaccines to injection drug users at a syringe exchangeJournal of Substance Abuse Treatment, 2000
- Organizational Issues in Conducting Tuberculosis Screening at a Syringe Exchange ProgramJournal of Substance Abuse Treatment, 1998
- Adherence to tuberculosis preventive therapy among HIV-infected persons in Chiang Rai, ThailandAIDS, 1997
- Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and MedicineJAMA, 1996
- Successful Adherence to Observed Prophylaxis and Treatment of Tuberculosis Among Drug Users in a Methadone ProgramJournal of Addictive Diseases, 1996
- Tuberculosis in Drug UsersClinical Infectious Diseases, 1995
- Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA)JAMA, 1995
- A prospective study of the risk of tuberculosis among HIV-infected patientsAIDS, 1993
- Risk Factors for Human Immunodeficiency Virus Infection in Intravenous Drug UsersNew England Journal of Medicine, 1989
- A Prospective Study of the Risk of Tuberculosis among Intravenous Drug Users with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1989